VIRX (Viracta Therapeutics) Valuation Rank

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Viracta Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (OTCPK:VIRX) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Executives

Daniel R. Chevallard	officer: Chief Executive Officer	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mark Rothera	director, officer: President and CEO	C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Darrel P. Cohen	officer: Chief Medical Officer	C/O VIRACTA THERAPEUTICS, INC., 2533 S. COAST HWY 101, SUITE 210, CARDIFF CA 92007
Lisa Rojkjaer	officer: Chief Medical Officer	C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Ivor Royston	director, officer: CEO & President	4401 WILSHIRE BLVD., SUITE 200, LOS ANGELES CA 90010
Jane Chung	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Flavia Borellini	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Stephen Rubino	director	C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Gur Roshwalb	director, 10 percent owner	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael Huang	director	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Thomas E Darcy	director	C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121